Blueprint Medicines Co. (NASDAQ:BPMC) Shares Acquired by Fox Run Management L.L.C.

Fox Run Management L.L.C. raised its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 262.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,264 shares of the biotechnology company's stock after purchasing an additional 7,434 shares during the quarter. Fox Run Management L.L.C.'s holdings in Blueprint Medicines were worth $895,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Wellington Management Group LLP lifted its position in Blueprint Medicines by 22.5% in the third quarter. Wellington Management Group LLP now owns 3,964,610 shares of the biotechnology company's stock valued at $366,726,000 after buying an additional 729,055 shares during the last quarter. State Street Corp boosted its position in shares of Blueprint Medicines by 16.2% during the 3rd quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company's stock worth $255,827,000 after purchasing an additional 385,818 shares during the period. William Blair Investment Management LLC increased its holdings in Blueprint Medicines by 16.1% in the 4th quarter. William Blair Investment Management LLC now owns 1,944,695 shares of the biotechnology company's stock valued at $169,616,000 after purchasing an additional 269,896 shares during the last quarter. Geode Capital Management LLC raised its position in Blueprint Medicines by 1.4% in the third quarter. Geode Capital Management LLC now owns 1,480,187 shares of the biotechnology company's stock valued at $136,942,000 after purchasing an additional 20,703 shares during the period. Finally, American Century Companies Inc. lifted its stake in Blueprint Medicines by 3.0% during the fourth quarter. American Century Companies Inc. now owns 839,203 shares of the biotechnology company's stock worth $73,195,000 after purchasing an additional 24,132 shares in the last quarter.

Remove Ads

Blueprint Medicines Stock Performance

BPMC traded down $0.99 on Thursday, reaching $89.73. The company had a trading volume of 651,991 shares, compared to its average volume of 712,083. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. Blueprint Medicines Co. has a 1 year low of $80.68 and a 1 year high of $121.90. The stock has a market capitalization of $5.73 billion, a PE ratio of -83.08 and a beta of 0.58. The stock has a 50-day moving average price of $98.84 and a 200-day moving average price of $93.95.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. As a group, research analysts forecast that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Insider Activity

In related news, COO Christina Rossi sold 2,274 shares of the business's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $95.02, for a total value of $216,075.48. Following the transaction, the chief operating officer now owns 69,266 shares in the company, valued at $6,581,655.32. The trade was a 3.18 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Ariel Hurley sold 3,203 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $92.62, for a total value of $296,661.86. Following the sale, the insider now directly owns 18,270 shares of the company's stock, valued at $1,692,167.40. The trade was a 14.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 31,608 shares of company stock valued at $3,319,587 in the last ninety days. 4.21% of the stock is currently owned by company insiders.

Analyst Ratings Changes

BPMC has been the topic of several research analyst reports. JMP Securities reiterated a "market outperform" rating and issued a $125.00 price objective on shares of Blueprint Medicines in a report on Friday, February 14th. Wedbush reiterated an "outperform" rating and set a $128.00 price target on shares of Blueprint Medicines in a research note on Friday, February 28th. Guggenheim reissued a "buy" rating on shares of Blueprint Medicines in a research note on Wednesday, December 11th. Jefferies Financial Group started coverage on shares of Blueprint Medicines in a report on Monday, March 17th. They issued a "buy" rating and a $135.00 price objective for the company. Finally, Scotiabank initiated coverage on shares of Blueprint Medicines in a report on Friday, March 7th. They set a "sector outperform" rating and a $150.00 target price on the stock. Two analysts have rated the stock with a sell rating, six have given a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $124.95.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.